These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22811299)

  • 21. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
    Nowacek AS; Balkundi S; McMillan J; Roy U; Martinez-Skinner A; Mosley RL; Kanmogne G; Kabanov AV; Bronich T; Gendelman HE
    J Control Release; 2011 Mar; 150(2):204-11. PubMed ID: 21108978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy.
    Araínga M; Edagwa B; Mosley RL; Poluektova LY; Gorantla S; Gendelman HE
    Retrovirology; 2017 Mar; 14(1):17. PubMed ID: 28279181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.
    Jacobson JM; Kuritzkes DR; Godofsky E; DeJesus E; Larson JA; Weinheimer SP; Lewis ST
    Antimicrob Agents Chemother; 2009 Feb; 53(2):450-7. PubMed ID: 19015347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.
    Asahchop EL; Meziane O; Mamik MK; Chan WF; Branton WG; Resch L; Gill MJ; Haddad E; Guimond JV; Wainberg MA; Baker GB; Cohen EA; Power C
    Retrovirology; 2017 Oct; 14(1):47. PubMed ID: 29037245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.
    Madelain V; Le MP; Champenois K; Charpentier C; Landman R; Joly V; Yeni P; Descamps D; Yazdanpanah Y; Peytavin G
    J Antimicrob Chemother; 2017 Apr; 72(4):1137-1146. PubMed ID: 28065890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy.
    Pohling J; Zipperlen K; Hollett NA; Gallant ME; Grant MD
    BMC Infect Dis; 2010 May; 10():129. PubMed ID: 20500844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
    Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.
    Stoddart CA; Bales CA; Bare JC; Chkhenkeli G; Galkina SA; Kinkade AN; Moreno ME; Rivera JM; Ronquillo RE; Sloan B; Black PL
    PLoS One; 2007 Aug; 2(7):e655. PubMed ID: 17668043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.
    Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Pisapia M; Delbeke E
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):44-55. PubMed ID: 11176268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
    Martinez-Skinner AL; Araínga MA; Puligujja P; Palandri DL; Baldridge HM; Edagwa BJ; McMillan JM; Mosley RL; Gendelman HE
    PLoS One; 2015; 10(12):e0145966. PubMed ID: 26716700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
    D'Amico R; Yang Y; Mildvan D; Evans SR; Schnizlein-Bick CT; Hafner R; Webb N; Basar M; Zackin R; Jacobson MA
    J Clin Immunol; 2005 Mar; 25(2):106-15. PubMed ID: 15821887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.
    Martinez-Skinner AL; Veerubhotla RS; Liu H; Xiong H; Yu F; McMillan JM; Gendelman HE
    J Proteome Res; 2013 May; 12(5):2282-94. PubMed ID: 23544708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
    J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
    Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F
    AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy.
    Amado RG; Jamieson BD; Cortado R; Cole SW; Zack JA
    J Virol; 1999 Aug; 73(8):6361-9. PubMed ID: 10400728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells.
    Verhoeven D; Sankaran S; Silvey M; Dandekar S
    J Virol; 2008 Apr; 82(8):4016-27. PubMed ID: 18272585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.